Clinical Guidelines

Light-activated Suprachoroidal Therapy for the First-line Treatment of Indeterminate Lesions and Small Choroidal Melanoma

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

1

AU-011 is a novel virus-like drug conjugate (VDC) for treating indeterminate lesions and small choroidal melanomas with a dual mechanism of action.
2

The preliminary safety data from the ongoing phase 2 trial using suprachoroidal administration supports the continued dose escalation.
3

AU-011 may hold potential for treating choroidal metastasis, indicating an innovative approach in ocular oncology.
4

The VDC's tumor targeting is driven by its binding to modified heparan sulfate proteoglycans on the tumor cell membrane.
5

The article is part of a series supported by Bausch + Lomb, with authors Hakan Demirci, MD, and Buse Guneri Beser, MD.

Original Source(s)

Retinal Physician

Light-activated Suprachoroidal Therapy for the First-line Treatment of Indeterminate Lesions and Small Choroidal Melanoma

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.